Comparing Lexicon Pharmaceuticals (LXRX) and Its Rivals
Lexicon Pharmaceuticals (NASDAQ: LXRX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Lexicon Pharmaceuticals to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.
This table compares Lexicon Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Lexicon Pharmaceuticals Competitors||-5,313.56%||-219.98%||-40.02%|
This is a breakdown of current recommendations for Lexicon Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Lexicon Pharmaceuticals Competitors||857||3201||11604||231||2.71|
Lexicon Pharmaceuticals currently has a consensus target price of $28.50, indicating a potential upside of 172.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.93%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than its competitors.
Insider & Institutional Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.8% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Lexicon Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Lexicon Pharmaceuticals||$83.34 million||-$141.42 million||-8.30|
|Lexicon Pharmaceuticals Competitors||$284.28 million||$34.29 million||78.12|
Lexicon Pharmaceuticals’ competitors have higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Lexicon Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals’ competitors have a beta of 0.53, indicating that their average share price is 47% less volatile than the S&P 500.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.